Novo Nordisk Acquires Embark Biotech to Boost Obesity and Cardiometabolic Drug Development
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the purchase of compatriot Embark Biotech,...
Novo Nordisk
CSPC Pharmaceutical’s Biosimilar Ozempic Equivalent Gets NMPA Clinical Trial Approval
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its biosimilar version of Novo...
Novo Nordisk to Acquire Inversago Pharma in a Deal Valued Up to USD 1.1 Billion
Denmark’s leading pharmaceutical company, Novo Nordisk (NYSE: NVO), has reached an agreement to acquire Canada-based...
Novo Nordisk’s H1 2023 Financials Show 30% YOY Growth Driven by GLP-1 Drugs and Obesity Sales
Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has announced its financial results for the...
Novo Nordisk’s Wegovy Demonstrates 20% Reduction in Cardiovascular Events in SELECT Trial
Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has released topline data supporting the use...
Shanghai Benemae’s Benaglutide Approved by NMPA for Adult Weight Management in China
The National Medical Products Administration (NMPA) has indicated on its website that benaglutide, developed by...
Novo Nordisk’s Turoctocog Alfa Pegol for Hemophilia A Accepted for Review by China’s CDE
The Center for Drug Evaluation (CDE) in China has indicated on its website that the...
China’s MofCOM Hosts Symposium with Multinational Corporations, Promises Development Opportunities
This week, China’s Ministry of Commerce (MofCOM) convened a symposium attended by representatives from a...
Huadong Medicine’s Liraglutide Biosimilar Gains NMPA Approval for Weight Loss Indication
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received additional indication...
Hybio Pharmaceutical’s Liraglutide Biosimilar Withdrawn from NMPA Filing
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...
Beijing Tiantan Biological Completes Phase I Study for Recombinant Coagulation Factor VIIa
China-based Beijing Tiantan Biological Products Co., Ltd (SHA: 600161) has announced the conclusion of a...
Hybio Pharmaceutical’s Semaglutide API Receives FDA Review Acceptance
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the US Food and Drug...
Novo Nordisk’s Semaglutide for Weight Loss Accepted for Review by China’s NMPA
Denmark-headquartered Novo Nordisk (NYSE: NVO) has announced that its market filing for the glucagon-like peptide-1...
Huadong Medicine’s Patent Challenge Against Novo Nordisk’s Ozempic Heads to Hearing
February 23 will mark the oral hearing phase for the patent challenge case brought by...
Novo Nordisk Posts Strong 2022 Results; GLP-1 Therapies Drive Growth
Denmark-based diabetes giant Novo Nordisk (NYSE: NVO) has reported financial results for the fourth quarter...
Sanofi’s iGlarLixi Approved in China for Type 2 Diabetes Management
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that the National Medical Products Administration (NMPA)...
Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...
Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance
Denmark-based biopharma Novo Nordisk A/S (NYSE: NVO) has released its Q3 2022 earnings report. The...
Novo Nordisk Partners with Shanghai Pharma for Smart Logistics at CIIE
Novo Nordisk (NYSE: NVO) has announced a strategic partnership with China’s Shanghai Pharmaceuticals (HKG: 2607,...
Novo Nordisk to Invest RMB 400M in Shanghai at CIIE
Novo Nordisk (NYSE: NVO) has announced at the 5th China International Import Expo (CIIE) an...